Regulation of Arginine-vasopressin (AVP)

Depression Clinical Trial

— REGAVP  

Official title:

Regulation of Arginine-vasopressin (AVP) in Psychiatric Disorders

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02626832
• Other study ID #: 0910005875
• Status: Completed
• Phase: N/A
• First received: November 4, 2015
• Last updated: December 8, 2015
• Start date: February 2010
• Est. completion date: December 2014

Study information

• Verified date: December 2015
• Source: Yale University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

This study aims to develop a method for the assessment of central NMDA receptor functioning in patients with depression and schizophrenia. For this purpose a transitional approach is used based on preclinical studies that show a dose-dependent relationship between the activity of hypothalamic NMDA receptor and plasma AVP response to increasing plasma osmolality. Patients with schizophrenia, depression and healthy controls participated in this study. The Investigators found that in a subgroup of patients with schizophrenia the AVP response was low and that in a subgroup of subjects with depression the AVP response was high compared to healthy controls.

Description:

Evidence suggests that altered N-methyl-D-aspartate (NMDA) receptor activity and glutamate signaling may underlie the pathogenesis of both schizophrenia and depression at least in subgroups of patients. In schizophrenia, pharmacologic modeling, postmortem and imaging data suggest reduced NMDA signaling. In contrast, recent clinical trials demonstrating the efficacy of the NMDA antagonist ketamine in severely depressed patients suggest increased NMDA receptor signaling. The Investigators have conducted a proof of concept study to assess whether there is any in vivo evidence for an inverse association in depression and schizophrenia with respect to the NMDA receptor function. For this purpose the investigators used a translational approach, based on findings from animal studies that NMDA receptor is a key mediator of arginine-vasopressin (AVP) release into the bloodstream. Using hypertonic saline to induce AVP release, as done in animal studies, it was found that in a subgroup of depressed patients, NMDA receptor mediated AVP release was significantly increased, whereas in a subgroup of schizophrenia patients, the same response was abnormally low. Previous research has demonstrated that this response is well conserved. These findings are consistent with implicated NMDA receptor related abnormalities in depression and schizophrenia in subgroups of patients, and provide the first in vivo evidence towards this dichotomy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: December 2014
• Est. primary completion date: November 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 55 Years

Eligibility

Inclusion criteria for healthy controls:

• Ages of 18-55 years from all ethnic backgrounds.

• Male or female.

• Smoker or nonsmoker.

• Written informed consent.

Exclusion criteria for healthy controls:

• DSM-IV diagnosis of psychotic, anxiety, mood disorder.

• History of major psychiatric disorder in first-degree relatives.

• A history of significant medical/neurological disease. Unstable medical condition based on EKG, vital signs, physical examination and laboratory work-up (CBC with differential, SMA-7, uric acid, creatinine clearance, LFTs, TFTs, UA, Utox, Urine pregnancy test).

• A history of cardiac disease including arrhythmias; history of syncope or unexplained loss of consciousness; history of renal stones or renal failure; history of diabetes mellitus or diabetes insipidus.

• Subjects with hypertension (BP > 140/90).

• Current hyponatremia.

• Serum Ca2+ and uric acid levels that are above normal range.

• Serum creatinine outside of normal range for age.

• Creatinine clearance <70 ml/min using the Cockcroft-Gault equation (Cockcroft et al 1976) [(140-age)*(weight in kg)*(.85 if female)/(72*Cr)].

• Any medication that in the opinion of the PI could interfere with either the safety of the study and/or the outcome measures, such as diuretics of any type, lithium, carbamazepine.

• Current substance abuse/dependency determined by urine toxicology.

• Current treatment with medications with psychotropic effects.

• Current pregnancy, unsatisfactory birth control method report for females.

• IQ < 70 as determined by Wechsler Abbreviated Scale of Intelligence.

• Non-English speaking.

Inclusion criteria for patients with schizophrenia:

• Ages of 21-55 years from all ethnic backgrounds.

• Male or female.

• Smoker or nonsmoker.

• Written informed consent.

• DSM-IV diagnosis of schizophrenia or schizoaffective disorder.

• For treated patients: The patient has been on a stable dose of antipsychotics for the past month and does not require a change of medications or dose adjustment at study entry.

• For untreated patients: Has refused to be treated with medications, maintains regular clinic appointments with the clinicians, and does not pose an imminent danger to himself or others.

Exclusion criteria for patients with schizophrenia

• A history of significant medical/neurological disease. Unstable medical condition based on EKG, vital signs, physical examination and laboratory work-up (CBC with differential, SMA-7, uric acid, creatinine clearance, LFTs, TFTs, UA, Utox, Urine pregnancy test).

• A history of cardiac disease including arrhythmias; history of syncope or unexplained loss of consciousness; history of renal stones or renal failure; history of diabetes mellitus or diabetes insipidus.

• Serum Ca2+ and uric acid levels that are above normal range.

• Serum creatinine outside of normal range for age.

• Creatinine clearance <70 ml/min using the Cockcroft-Gault equation [(140-age)*(weight in kg)*(.85 if female)/(72*Cr)].

• Subjects with hypertension (BP > 140/90).

• Current hyponatremia.

• Any medication that in the opinion of the PI could interfere with either the safety of the study and/or the outcome measures, such as diuretics of any type, lithium, carbamazepine.

• Currently on clozapine as clozapine may interfere with brain water regulation (Leadbetter and Shutty, 1994).

• Current substance abuse/dependency determined by urine toxicology.

• Current pregnancy, unsatisfactory birth control method report for females.

• IQ < 70 as determined by Wechsler Abbreviated Scale of Intelligence.

• Non-English speaking.

Inclusion criteria for patients with depression:

• Ages of 21-55 years from all ethnic backgrounds.

• Male or female.

• Smoker or nonsmoker.

• Written informed consent.

• DSM-IV diagnosis of major depressive disorder, unipolar.

• For treated patients: The patient has been on a stable dose of medications (antidepressants) for the past month and does not require a change of medications or dose adjustment at study entry.

• For untreated patients: Has refused to be treated with medications, maintains regular clinic appointments with the clinicians, and does not pose an imminent danger to himself or others.

Exclusion criteria for patients with depression:

• A history of significant medical/neurological disease. Unstable medical condition based on EKG, vital signs, physical examination and laboratory work-up (CBC with differential, SMA-7, uric acid, creatinine clearance, LFTs, TFTs, UA, Utox, Urine pregnancy test).

• A history of cardiac disease including arrhythmias; history of syncope or unexplained loss of consciousness; history of renal stones or renal failure; history of diabetes mellitus or diabetes insipidus.

• Serum Ca2+ and uric acid levels that are above normal range.

• Serum creatinine outside of normal range for age.

• Creatinine clearance <70 ml/min using the Cockcroft-Gault equation [(140-age)*(weight in kg)*(.85 if female)/(72*Cr)].

• Subjects with hypertension (BP > 140/90).

• Current hyponatremia.

• Any medication that in the opinion of the PI could interfere with either the safety of the study and/or the outcome measures, such as diuretics of any type, lithium, carbamazepine.

• Current substance abuse/dependency determined by urine toxicology.

• Current pregnancy, unsatisfactory birth control method report for females.

• IQ < 70 as determined by Wechsler Abbreviated Scale of Intelligence.

• Non-English speaking.

Inclusion criteria for patients from the PRIME Clinic:

• Ages of 18-40 years from all ethnic backgrounds.

• Male or female.

• Smoker or nonsmoker.

• Written informed consent.

Exclusion criteria for patients from the PRIME Clinic:

• A history of significant medical/neurological disease. Unstable medical condition based on EKG, vital signs, physical examination and laboratory work-up (CBC with differential, SMA-7, uric acid, creatinine clearance, LFTs, TFTs, UA, Utox, Urine pregnancy test).

• A history of cardiac disease including arrhythmias; history of syncope or unexplained loss of consciousness; history of renal stones or renal failure; history of diabetes mellitus or diabetes insipidus.

• Serum Ca2+ and uric acid levels that are above normal range.

• Serum creatinine outside of normal range for age.

• Creatinine clearance <70 ml/min using the Cockcroft-Gault equation [(140-age)*(weight in kg)*(.85 if female)/(72*Cr)].

• Subjects with hypertension (BP > 140/90).

• Current hyponatremia.

• Any medication that in the opinion of the PI could interfere with either the safety of the study and/or the outcome measures, such as diuretics of any type, lithium, carbamazepine.

• Currently on clozapine as clozapine may interfere with brain water regulation (Leadbetter and Shutty, 1994).

• Current substance abuse/dependency determined by urine toxicology.

• Current pregnancy, unsatisfactory birth control method report for females.

• IQ < 70 as determined by Wechsler Abbreviated Scale of Intelligence.

• Non-English speaking.

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Depression
• Diabetes Insipidus
• Schizophrenia

Intervention

Other:
• Procedural
All subjects receive intravenous hypertonic saline and serial blood samples are drawn for AVP concentrations

Locations

Country	Name	City	State
United States	The John Pierce Laboratory	New Haven	Connecticut
United States	VA Connecticut Healthcare System	West Haven	Connecticut

Sponsors (3)

Lead Sponsor	Collaborator
Yale University	The John B. Pierce Laboratory, VA Connecticut Healthcare System

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AVP response to plasma osmolality as measured by slopes between the two variables		Within 3 months	No